Search the site

HOTLINE TELEPHONE NUMBER: 0-800-504-381 /Mon-Fri 9: 00-17: 00/


Capsules 400 mg, blister, No. 30

  1. Gamma-aminobutyric acid (GABA) 250 mg
  2. Ginkgo biloba leaf extract 40 mg
  3. Auxiliary substances (lactose, starch) 110

Conclusion of the State Sanitary and Epidemiological Expertise No. 05.03.02-04 / 70257 of 19.11.2014.
TU U 15.8-35768699-002: 2009


Consult a doctor before use



The action of  NEUROXYMETH® is determined by the properties of its gamma-aminobutyric acid (GABA) and the biologically active substances contained in the leaf extract of the medicinal plant of ginkgo biloba. 

The action of all active components of NEUROXYMETH® was  clinically confirmed.

Gamma-aminobutyric acid (GABA) is an amino acid that is contained in the central nervous system (CNS) and affects specific GABA receptors of nerve cells (neurons). 

Gamma-aminobutyric acid is the main mediator involved in the processes of inhibition in the central nervous system. Under its influence the energy processes in the brain  improve, as well as the utilization of glucose and the oxygen consumption of tissues  increases, the blood supply normalizes.

Gamma-aminobutyric acid has a mild nootropic effect and improves the dynamics of the nervous processes in the brain: it increases concentration of attention, improves process of thinking, memory, accelerates the recovery of movements and speech after cerebral circulatory disorders, has a mild psycho-stimulating effect. 

The extract of leaves of ginkgo biloba has a complex chemical composition, which includes more than 40 active components and has a multifaceted effect on the body. 

Flavonoids and terpenes, contained in the extract of leaves of ginkgo biloba, normalize the tone of blood vessels and reduce platelet aggregation, normalize microcirculation and rheological characteristics of blood, improving cerebral and coronary circulation; reduce the permeability of the vascular wall, exert antiedematous action as at the level of the brain as peripheral tissues. 

Active components of the extract of the leaves of ginkgo biloba have powerful antioxidant properties: they inactivate toxic free radicals and inhibit lipid peroxidation (LPO) of cell membranes, which slows down the process of cholesterol transformation into plaques, which subsequently reduces the lumen of the vessels. 

The extract of the leaves of ginkgo biloba normalizes the release of some neurotransmitters and their ability to bind to receptors, prevents the agerelated decrease in the number of M-cholinergic receptors and a2-adrenergic receptors, which significantly improves the conduct of nerve impulses. 

The complex effect of the leaf extract of ginkgo biloba explains its high therapeutic efficacy in a wide range of pathological conditions of the central nervous system and vascular disorders. 


Gamma-aminobutyric acid and the extract of ginkgo biloba leaves, which are the part of NEUROXIMETH®, are used for active prevention and in complex treatment:

- agerelated changes in cerebral vessels, manifested by impaired memory and mental abilities;

- dynamic disorders of cerebral circulation;

- dizziness and noise in the ears of vascular and involuntary origin;

- endogenous depressions, asthenic and anxiety-neurotic states;

- for the prevention of recurrences and complications in conditions after cerebral circulation disorders (strokes, craniocerebral trauma, etc.);

- in ophthalmology: in the complex treatment of vascular diseases of the retina and yellow spot, age-related macular degeneration (AMD), diabetic retinopathy, open-angle glaucoma;

- to improve mental performance, concentration, memory;

- for active prevention of the symptomatic complex of motion sickness (seasickness). 


adults 1 capsule three times a day for 5-10 minutes before meals, wash down with some water. The course of treatment is 30-40 days. Break is for 2 weeks. If necessary, the course can be repeated.

In case of prescribing by a doctor, you can use 2 capsules three times a day, as well as long-term use for 4-6 months.

Before use, consult a physician. 


Individual sensitivity to the components, children, pregnancy, women during lactation.


Allergic reactions to individual components of NEUROXIMETH®

In some cases, in the first days of use, there may be dyspeptic phenomena, fluctuations in blood pressure, a feeling of heat, a violation of sleep. With a decrease in dose, these phenomena tend to pass quickly. 


There is no sufficient information about the effect of NEUROXIMETH® on the ability to drive vehicles and mechanisms. Do not exceed the recommended dose. For people with erosive and ulcerative lesions of the gastrointestinal tract (GIT) and liver failure, prolonged use of NEUROXIMETH® is possible only under the supervision of a physician. 


When using NEUROXIMETH® in unreasonably high doses, are possible dyspeptic phenomena (nausea, vomiting, diarrhea). Symptomatic treatment, gastric lavage, taking of enterosorbents is consulted. 


There are no studies confirming the interaction of NEUROXIMETH® and its constituents with medicines. However, there are reports of a possible interaction of the extract of the leaves of ginkgo biloba with preparations that affect blood coagulability, and the possible enhancement of the action of narcotic analgesics, dormitives and anticonvulsants by gamma-aminobutyric acid. 


Store in the manufacturer's packaging in a dry, protected from light environment at a temperature of 18 ° C to 25 ° C and relative humidity not more than 75%, 24 months from the date of manufacture.

Keep out of the reach of children.

It is an Additive dietary complex to the diet. It is not a medicinal product. Dietary supplements should not be used as a substitute for a full-fledged diet. Do not exceed the recommended amount for daily intake. 

Conclusion of the State Sanitary and Epidemiological Expertise No. 05.03.02-04 / 70257 of 19.11.2014.

Detailed information on the use of NEUROXIMETH®

You can get by hot line phone number: 0-800-504-381,

Mon-Fri, from 10-00 to 16-00

(Free calls from all stationary phones on the territory of Ukraine)